MedPath

Nucleus Basalis Deep Brain Stimulation for Thinking & Memory Problems in Parkinson's.

Phase 1
Completed
Conditions
Dementia in Parkinson's Disease
Interventions
Device: NBM DBS
Registration Number
NCT01701544
Lead Sponsor
University College, London
Brief Summary

We will perform a pilot study to evaluate the effectiveness of human NBM DBS at improving cognitive deficits in PD patients referred and eligible for conventional DBS treatment for coexisting motor impairments. Six patients with PD with both motor fluctuations and cognitive impairments (including but not restricted to deficits in attention and working memory) will have bilateral electrodes implanted to ensure that superficial contacts lie in the conventional motor GPi target, while the deepest electrical contacts lie in the NBM- (see figure 1). We will place electrodes using our conventional image guided, stereotactic frame-based procedure currently used in patients at NHNN. Patients will be randomised into 2 groups in a crossover trial design to have 3 month periods of NBM stimulation switched on or switched off separated by a 1 month washout period, following which the patient will cross over to have the opposite condition for a further 3 months- see timeline. At the end of the crossover period, all patients will be invited for continued follow up with stimulation switched on and will have neuropsychological evaluations at 6 monthly intervals. Patients will be given the option of receiving additional conventional stimulation to the motor GPi, through the higher contacts of each electrode, at the end of the crossover period.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
6
Inclusion Criteria
  • All patients will meet Queen Square brain bank criteria for the diagnosis of PD and will have motor fluctuations (off periods and/or L-dopa induced dyskinesias) in response to medications that are known to improve with GPi DBS, and will be appropriate candidates for GPi DBS aside from the coexistence of cognitive impairment.

Patients will be aged between 35 and 80 years.

Patients will be able to give informed consent.

Patients will meet criteria for PD dementia. Patients will have a MMSE score between 26 and lower cutoff of 21 to restrict the sample to those with mild dementia and cognitive impairment. This will be equivalent to an age and education adjusted scaled score of greater than 5 and lower than 9 (mildly impaired range) on the Mattis Dementia Rating Scale-2.

Patients will have only minimal atrophy on pre-operative brain MRI scans.

Patients will be living at home and will have a carer living with them e.g. their spouse

Able to comply with trial protocol and willing to attend clinic necessary visits

Exclusion Criteria
  • Diagnosis or suspicion of other cause for parkinsonism or dementia.

Known abnormality on CT or MRI brain imaging considered likely to compromise compliance with trial protocol.

Prior intra-cerebral surgical intervention for Parkinson's disease including Deep Brain stimulation, lesional surgery, growth factor administration, gene therapy or cell transplant.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
NBM DBS OnNBM DBSNBM DBS Switched On
NBM DBS OffNBM DBSNBM DBS switched off
Primary Outcome Measures
NameTimeMethod
Abbreviated cognitive battery6 months

Differences between each item of the abbreviated cognitive battery scores between patients after 3 months ON stimulation and 3 months OFF stimulation.

CVLT-II,Verbal Fluency,Simple \& Choice RT (CANTAB),Digit span,Posner's covert attention test

Secondary Outcome Measures
NameTimeMethod
Minimental State Examination6 months
DRS-26 months

Dementia Rating Scale-2

SRM (Faces)6 months

Short Recognition Memory for faces

WAIS-III (Letter number sequencing, Arithmetic)6 months

Wechsler Abbreviated Scale of Intelligence

FAST6 months

Florida Apraxia Screening test

NPI6 months

Neuropsychiatric Inventory

BDS6 months

Blessed Dementia Scale

HAM-D6 months

Hamilton Depression scale

MDS UPDRS6 months

Movement Disorders Society - Unified Parkinson's disease Rating scale

PDQ396 months

Parkinson's disease quality of life questionnaire

GFQ6 months

Gait and falls questioannaire

NMS Quest6 months

Non Motor Symptoms Questionnaire

Trial Locations

Locations (1)

National Hospital for Neurology & Neurosurgery

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath